Biosimilars’ Next Hurdle In EU Is Physician Opposition To Extrapolation
Executive Summary
As Europe gears up to approve and publish a global development plan for biosimilars, doctors’ reluctance to support extrapolation of indications for these drugs could be costly stumbling block for industry.